Compare MGIH & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGIH | LSTA |
|---|---|---|
| Founded | 1978 | 1980 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4M | 16.4M |
| IPO Year | 2023 | N/A |
| Metric | MGIH | LSTA |
|---|---|---|
| Price | $1.42 | $4.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 55.6K | ★ 394.1K |
| Earning Date | 10-28-2025 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $25,334,149.00 | $1,070,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.11 | $1.81 |
| 52 Week High | $4.84 | $4.89 |
| Indicator | MGIH | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 55.59 | 78.30 |
| Support Level | $1.41 | $4.51 |
| Resistance Level | $1.61 | $4.79 |
| Average True Range (ATR) | 0.12 | 0.15 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 34.15 | 31.62 |
Millennium Group International Holdings Ltd supplies paper-based packaging solutions, including inner packaging boxes produced with offset or flexo printing and outer corrugated boxes used for transportation, storage, pallets, and point-of-purchase displays. The company manufactures corrugated products of different sizes, shapes, thicknesses, and strengths according to customer specifications. It also operates a supply chain management business in Vietnam to service international clients who source their packaging needs from Vietnam and other ASEAN countries. The corrugated paper is durable, versatile, economical, and lightweight.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.